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ABSTRACT
The activity of WCK 771, a new experimental quinolone being developed to overcome quinolone
resistance in staphylococci, against quinolone-susceptible and -resistant pneumococci was determined.
Comparative activities of ciproﬂoxacin, levoﬂoxacin, gatiﬂoxacin, moxiﬂoxacin, clinaﬂoxacin, vanco-
mycin, linezolid, amoxycillin, cefuroxime, azithromycin and clarithromycin were determined with MIC
and time-kill experiments. Animal experiments were also performed to test the in-vivo anti-
pneumococcal activity of WCK 771 compared to levoﬂoxacin. WCK 771 MIC50 ⁄ 90 values for 300
quinolone-susceptible Streptococcus pneumoniae isolates (108 penicillin-susceptible, 92 penicillin-inter-
mediate and 100 penicillin-resistant) were 0.5 ⁄ 0.5 mg ⁄L; the MICs of b-lactams and macrolides rose with
those of penicillin G, and all isolates were susceptible to vancomycin and linezolid. WCK 771 MIC50 ⁄ 90
values for 25 quinolone-resistant pneumococcal isolates were 4 ⁄ 8 mg ⁄L, compared to 0.5 ⁄ 1 mg ⁄L for
clinaﬂoxacin, 2 ⁄ 4 mg ⁄L for gatiﬂoxacin and moxiﬂoxacin, 8 ⁄ 16 mg ⁄L for levoﬂoxacin, and
16 ⁄>32 mg ⁄L for ciproﬂoxacin. Time-kill studies showed that WCK 771 was bactericidal against
pneumococci after 24 h at 4· MIC, as were the other quinolones tested. Animal model studies showed
that WCK 771 had efﬁcacy comparable to that of levoﬂoxacin, by both the oral and subcutaneous routes,
for systemic infection caused by three quinolone-susceptible isolates of pneumococci. Overall, WCK 771
was potent both in vivo and in vitro against quinolone-susceptible, but not quinolone-resistant,
S. pneumoniae, regardless of penicillin susceptibility.
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INTRODUCTION
As the prevalence of multiresistant strains of
Streptococcus pneumoniae has increased world-
wide, there has been an attendant need for new
antimicrobial agents. Introduced in the 1980s,
ﬂuoroquinolones fulﬁlled this need initially, and
these agents are still important for the treatment
of a wide range of infections. However, resistance
to many members of this class of agent is
emerging in pneumococci [1,2], although the
prevalence of resistance remains low (< 2%) in
most parts of the world [2–7]. Pneumococcal
resistance to penicillin G and other b-lactam and
non-b-lactam compounds has also increased
worldwide, including in the USA. Major foci of
resistance include South Africa, Spain and central
and eastern Europe [3–5]. In the USA, surveys
have shown an increase in resistance to penicillin
(including resistance classed as penicillin-inter-
mediate) from <5% before 1989 to 6.6% in 1991–
1992 and, more recently, to 28.7–37% [6,7]. The
problem of drug-resistant pneumococci is com-
pounded by the spread of resistant clones from
country to country and worldwide [8–10].
There is a need for oral compounds for outpa-
tient treatment of respiratory tract infections
caused by penicillin- and macrolide-resistant
pneumococci [11,12]. Older quinolones, such as
ciproﬂoxacin and oﬂoxacin, have only moderate
activity in vitro against pneumococci, with MICs
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clustering around resistance breakpoints. Newer
quinolones, such as levoﬂoxacin, gatiﬂoxacin,
moxiﬂoxacin and gemiﬂoxacin, have greater anti-
pneumococcal activity than the older agents
[4,5,13–19]. However, recent reports from Hong
Kong [20], Canada [21] and Spain [22] have
described an increasing prevalence of quinolone-
resistant pneumococci. Quinolone resistance in
S. pneumoniae is mediated by stepwise changes in
the quinolone resistance-determining regions of
type II topoisomerase; mutations in parC and gyrA
are commonest, but parE and gyrB mutations are
also encountered [2]. The prevalence of resistant
strains is likely to increase with increased use of
broad-spectrum quinolones for empirical therapy
of community-acquired respiratory tract infec-
tions.
WCK 771 (Fig. 1; Wockhardt Research Centre,
Aurangabad, India), the hydrate of the arginine
salt of S-(–)-nadiﬂoxacin, is a new experimental
quinolone with excellent anti-staphylococcal
activity that is undergoing phase I studies in
India as a parenteral antibacterial agent. The
present study sought to shed more light on the
activity of WCK 771 against Gram-positive bac-
teria by examining its activity against S. pneumo-
niae isolates with differing susceptibilities to
penicillin G and quinolones in comparison with
ciproﬂoxacin, levoﬂoxacin, gatiﬂoxacin, moxiﬂ-
oxacin, clinaﬂoxacin, vancomycin and linezolid.
Additionally, nine pneumococcal isolates were
tested in time-kill experiments with all six quino-
lones. Finally, the in-vivo efﬁcacy of WCK 771
was assessed in comparison with levoﬂoxacin in a
mouse systemic infection model with three quino-
lone-susceptible pneumococcal isolates, as well as
in a lung pneumococcal load-reduction study.
MATERIALS AND METHODS
Bacterial isolates
The isolates tested comprised 300 quinolone-susceptible and
25 quinolone-resistant S. pneumoniae. All isolates were from
clinical specimens (sputum, bronchial and tracheal aspirates,
eye cultures, blood, cerebrospinal ﬂuid) obtained from
patients from throughout the USA and countries in western
Europe during 1998–2002. Quinolone-susceptible isolates
were deﬁned as those with ciproﬂoxacin MICs £ 2.0 mg ⁄L,
and quinolone-resistant isolates as those with MICs
‡ 4 mg ⁄L [23]. Among the 300 quinolone-susceptible isolates,
108 were penicillin-susceptible (MICs £ 0.06 mg ⁄L), 92 were
penicillin-intermediate (MICs 0.12–1.0 mg ⁄L), and 100 were
penicillin-resistant (MICs 2.0–16.0 mg ⁄L). All penicillin-sus-
ceptible pneumococci were recent isolates from the USA,
while penicillin-intermediate and -resistant pneumococci
were recent isolates from the USA, South Africa, Spain,
France, central and eastern Europe and Korea. The 25
quinolone-resistant pneumococcal isolates were selected
from our collection. Mechanisms of quinolone resistance
for these isolates included alterations in the quinolone-
resistance-determining regions of ParC, GyrA, ParE and ⁄ or
GyrB. Mutations in parC were at S79F, S79Y, D83N, D83G,
N91D, R95C or K137N. Mutations in gyrA were at S81A,
S81C, S81F, S81Y, E85K or S114G. Nineteen isolates had a
mutation in parE at D435N or I460V. Only one isolate had a
mutation in gyrB at E474K. Nineteen isolates had a total of
three or four mutations in the quinolone-resistance-deter-
mining regions of parC, gyrA, parE, and ⁄or gyrB.
Antimicrobial agents and MIC testing
WCK 771 was synthesised at Wockhardt Research Centre,
Aurangabad, India. Other antimicrobial agents were either
synthesised at Wockhardt Research Centre (clinaﬂoxacin) or
obtained from their respective manufacturers. Agar dilution
testing was performed on Mueller–Hinton agar (BBL Micro-
biology Systems, Cockeysville, MD, USA) supplemented with
sheep blood 5% v ⁄v, with incubation in air for 24 h [23]. MICs
of the pneumococci tested with time-kill kinetics were deter-
mined by broth microdilution in Mueller–Hinton broth (BBL
Microbiology Systems) supplemented with sheep blood 5%
v ⁄v. Standard quality control strains, including S. pneumoniae
ATCC 49619, were included in each batch of agar or broth
microdilution tests [23]. Data were interpreted according to
standard recommendations [24].
Determination of the efﬂux mechanism of quinolone-
resistant pneumococci
Quinolone MICs for quinolone-resistant pneumococci were
determined in the presence and absence of reserpine (Sigma,
St Louis, MO, USA) 10 mg ⁄L as described previously [25–27].
The agents tested were WCK 771, ciproﬂoxacin, levoﬂoxacin,
gatiﬂoxacin, moxiﬂoxacin and clinaﬂoxacin. The existence of
an efﬂux system was recognised by a quinolone MIC that was
at least four-fold lower in the presence of reserpine compared
to theMICwithout reserpine. Testingwas repeated three times.
Time-kill testing
The time-kill activity of quinolones was tested against nine
selected pneumococcal isolates, in Mueller–Hinton broth with
lysed horse blood 5% v ⁄v, as described previously [28]. The
isolates tested included three penicillin-susceptible, three peni-
cillin-intermediate and three penicillin-resistant isolates. One of
the penicillin-resistant isolates was also quinolone-resistant,
with a ciproﬂoxacin MIC of 32 mg ⁄L. This latter isolate had
mutations in gyrA (S81Y), parC (S79F, K137N) and parE (I460V).
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Fig. 1. Chemical structure of WCK 771.
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Antibiotic concentrations were chosen to provide three doub-
ling dilutions above and one dilution below the previously
determined MIC. Growth controls with inoculum but no
antibiotic were included in each experiment [28]. The original
viable count was determined with use of the untreated growth
control.Only inoculawithin the range5 · 105 - 5 · 106 CFU ⁄mL
were acceptable [28], and testing of out-of-range samples was
repeated. Viability counts of antibiotic-containing suspensions
were performed at 0, 3, 6 and 24 h. Colony counts were
performed on plates yielding 30–300 colonies. The lower
sensitivity limit of colony counts was 300 CFU ⁄mL [28].
The results of time-kill assays were analysed by determining
the number of strains which yielded Dlog10 CFU ⁄mL reduc-
tions of ) 1, ) 2 and ) 3 at 3, 6, 12 and 24 h respectively,
compared to baseline counts (0 h). Antimicrobial agents were
considered bactericidal at the lowest concentration that reduced
the original inoculum by ‡ 3 log10 CFU ⁄mL (99.9%) at each of
the time periods, and bacteriostatic if the inoculumwas reduced
by < 3 log10 CFU ⁄mL. The problem of drug carryover was
addressed by dilution, as described previously [28].
Systemic infection model
The comparative in-vivo efﬁcacies of WCK 771 and levoﬂoxa-
cin were studied in an intraperitoneal mouse septicaemia
model with the use of three quinolone-susceptible S. pneumo-
niae strains, SPN 727, SPN 731 and SPN 733. Treatment was
given 1 h and 4 h post-infection by the subcutaneous and oral
routes for each respective group. Survival was monitored until
day 7, and 50% effective dose (ED50) and 90% effective dose
(ED90) values with 95% conﬁdence intervals were calculated
by probit analysis [29] and the method of Litchﬁeld and
Wilcoxin [30], respectively.
Lung load-reduction study
Ten Swiss mice weighing 18–22 g were infected
(3 · 104 CFU ⁄ animal) with S. pneumoniae strain 6303 (type 3)
by the intraperitoneal route. Treatment was given 1 h and 4 h
post-infection with an oral dose of either 75 or 100 mg ⁄ kg,
twice-daily for 2 days, for both WCK 771 and levoﬂoxacin. The
animals were killed humanely 24 h after the last dose, and
lungs were excised and homogenised in 5 mL of chilled saline.
Viable counts in lung homogenates were determined in terms
of lung load ⁄ animal. The percentage of animals showing
sterile lungs (a count of £ 10 CFU ⁄mL) was calculated for
WCK 771 and levoﬂoxacin (Fig. 2).
RESULTS
MICs for the 300 quinolone-susceptible S. pneumo-
niae isolates are presented in Table 1. Clinaﬂoxacin
had the lowest MICs of all quinolones tested
(MIC50 and MIC90 both 0.12 mg ⁄L), followed by
moxiﬂoxacin (0.12 ⁄ 0.25 mg ⁄L), gatiﬂoxacin
(0.25 ⁄ 0.25 mg ⁄L), WCK 771 (0.5 ⁄ 0.5 mg ⁄L), levo-
ﬂoxacin (1 ⁄ 1 mg ⁄L) and ciproﬂoxacin (1 ⁄ 2 mg ⁄L).
MICs of b-lactams and macrolides rose with those
of penicillin G, and all isolates were susceptible to
vancomycin and linezolid.
For the 25 quinolone-resistant pneumococcal
isolates (ciproﬂoxacin MICs ‡ 4 mg ⁄L), clinaﬂoxa-
cin had the lowest MICs (range 0.25–1.0 mg ⁄L,
MIC50 ⁄ 90 0.5 ⁄ 1 mg ⁄L). MICs of the other quinolo-
nes ranged between 0.25 and > 32 mg ⁄L, with
MIC50 ⁄ 90 values of 2 ⁄ 4 mg ⁄L for moxiﬂoxacin,
2 ⁄ 4 mg ⁄L for gatiﬂoxacin, 4 ⁄ 8 mg ⁄L for WCK
771, 8 ⁄ 16 mg ⁄L for levoﬂoxacin, and
16 ⁄> 32 mg ⁄L for ciproﬂoxacin (Table 2). In 12 of
the 25 quinolone-resistant isolates, evidence was
found for the presence of an efﬂux mechanism for
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Fig. 2. Percentage of mice with sterile lungs following
exposure to Streptococcus pneumoniae strain 6303. MIC
(mg ⁄L): WCK 771, 0.25; levoﬂoxacin (Levo), 1.0. Route of
infection: intraperitoneal. Route of treatment: oral.
Table 1. Agar dilution MICs (mg ⁄L) for 300 quinolone-
susceptible Streptococcus pneumoniae isolatesa
Antimicrobial agent MIC range MIC50 MIC90
WCK 771 0.12–1 0.5 0.5
Ciproﬂoxacin 0.25–2 1 2
Levoﬂoxacin 0.5–2 1 1
Gatiﬂoxacin 0.06–0.25 0.25 0.25
Moxiﬂoxacin 0.06–0.5 0.12 0.25
Clinaﬂoxacin 0.016–0.25 0.12 0.12
Penicillinb
Penicillin S £ 0.008–0.06 0.03 0.03
Penicillin I 0.12–1 0.25 1.0
Penicillin R 2–16 2 4
Amoxycillin
Penicillin S £ 0.008–0.06 0.016 0.03
Penicillin I 0.03–1 0.12 1
Penicillin R 0.5–16 2 4
Cefuroxime
Penicillin S £ 0.008–2 0.03 0.06
Penicillin I 0.12–4 0.5 2
Penicillin R 2–32 4 16
Azithromycin
Penicillin S £ 0.008 to > 64 0.06 4
Penicillin I 0.03 to > 64 0.06 > 64
Penicillin R 0.03 to > 64 > 64 > 64
Clarithromycin
Penicillin S £ 0.008to > 64 0.03 2
Penicillin I 0.016 to > 64 0.03 64
Penicillin R 0.016 to > 64 8 > 64
Vancomycin 0.06–0.5 0.25 0.5
Linezolid 0.03–2 1 2
aCiproﬂoxacin MICs £ 2.0 mg ⁄L.
b108 penicillin-susceptible, 92 penicillin-intermediate and 100 penicillin-resistant
isolates.
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some of the quinolones tested, but MICs of WCK
771 were unaffected by the presence of reserpine.
In the presence of reserpine, 11 of the 25 isolates
had lower ciproﬂoxacin MICs (four- to 16-fold),
three had lower clinaﬂoxacin MICs (four- to eight-
fold), two had lower gatiﬂoxacin and levoﬂoxacin
MICs (four-fold), and one had a lower moxiﬂoxa-
cin MIC (four-fold).
Microdilution MICs for the nine S. pneumoniae
isolates tested in time-kill experiments are pre-
sented in Table 3. Time-kill analysis showed that
WCK 771 was bactericidal (99.9% killing) at 2·
MIC after 24 h with all nine pneumococcal isolates
tested, including the quinolone-resistant isolate
with deﬁned mutations in type II topoisomerase
(Table 4). Other quinolones gave similar time-kill
kinetics relative to their differing MICs.
The comparative in-vivo efﬁcacies of WCK 771
and levoﬂoxacin against three pneumococcal iso-
lates are shown in Table 5. The efﬁcacy of WCK
771 administered by the subcutaneous and oral
routes was comparable to that of levoﬂoxacin,
with both having ED50 values in the range
3–50 mg ⁄kg. In a lung load-reduction study with
S. pneumoniae strain 6303 and an oral dose of
75 mg ⁄ kg (Fig. 2), levoﬂoxacin resulted in sterile
Table 2. Agar dilution MICs (mg ⁄L) for 25 ciproﬂoxacin-
resistant Streptococcus pneumoniae isolatesa
Quinolone MIC range MIC50 MIC90
WCK 771 0.25–8.0 4.0 8.0
Ciproﬂoxacin 4.0 to > 32.0 16.0 > 32.0
Levoﬂoxacin 4.0–32.0 8.0 16.0
Gatiﬂoxacin 0.25–4.0 2.0 4.0
Moxiﬂoxacin 0.25–4.0 2.0 4.0
Clinaﬂoxacin 0.25–1.0 0.5 1.0
aCiproﬂoxacin MICs ‡ 4.0 mg ⁄L.
Table 3. MICs for Streptococcus pneumoniae isolates tested
in time-kill experiments (n = 9), including one quinolone-
resistant isolate
Agent
MICs (mg ⁄L) for each isolate
1 2 3 4 5 6 7 8 9
Penicillin G 0.03 £ 0.015 £ 0.015 0.12 0.25 0.5 2.0 4.0 4.0
WCK 771 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 8.0
Ciproﬂoxacin 1.0 1.0 1.0 1.0 2.0 2.0 1.0 1.0 32.0
Levoﬂoxacin 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 16.0
Gatiﬂoxacin 0.25 0.25 0.25 0.25 0.5 0.5 0.25 0.25 8.0
Moxiﬂoxacin 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 4.0
Clinaﬂoxacin 0.06 0.06 0.06 0.06 0.12 0.12 0.06 0.06 0.5
Table 4. Streptococcus pneumoniae time-kill results for nine
isolates, showing the numbers of isolates with 1, 2 and
3 log10 decreases in viable counts in relation to MICs at the
time-points indicated
Agent
3 h 6 h 12 h 24 h
) 1a ) 2a ) 3a ) 1 ) 2 ) 3 ) 1 ) 2 ) 3 ) 1 ) 2 ) 3
WCK 771A
4· MIC 9 7 0 9 9 2 9 9 7 9 9 9
2· MIC 9 4 0 9 8 2 9 9 6 9 9 9
MIC 7 3 0 9 5 0 9 8 6 8 5 3
Ciproﬂoxacin
4· MIC 9 5 0 9 9 2 9 9 6 9 9 9
2· MIC 9 4 0 9 6 1 9 9 5 9 9 8
MIC 6 0 0 8 5 0 9 8 4 6 3 2
Levoﬂoxacin
4· MIC 9 6 0 9 9 2 9 9 6 9 9 9
2· MIC 8 4 0 9 6 2 9 8 5 9 9 9
MIC 7 3 0 9 6 0 9 7 4 9 8 6
Gatiﬂoxacin
4· MIC 9 5 0 9 9 2 9 9 6 9 9 9
2· MIC 9 3 0 9 6 0 9 9 5 9 9 9
MIC 5 0 0 8 2 0 8 8 4 8 8 3
Moxiﬂoxacin
4· MIC 9 5 0 9 7 2 9 9 7 9 9 9
2· MIC 9 1 0 9 4 1 9 9 7 9 9 9
MIC 3 0 0 5 0 0 9 7 2 6 6 2
Clinaﬂoxacin
4· MIC 9 6 1 9 9 4 9 9 7 9 9 9
2· MIC 9 3 0 9 8 2 9 9 6 9 9 9
MIC 4 0 0 8 2 0 9 8 3 7 6 2
a90%, 99%, 99.9% killing.
Table 5. In-vivo efﬁcacy of WCK
771 for the treatment of Streptococcus
pneumoniae infectionsa
Strain Quinolone
MIC
(mg ⁄L)b
Effective subcutaneous dose
(mg ⁄kg) (95% CI)
Effective oral dose (mg ⁄kg)
(95% CI)
ED50 ED90 ED50 ED90
SPN 727
(type 19)
WCK 771 0.125 3.6
(1.2–8.1)
9.3
(4.5–21.3)
11.8
(8.5–16.5)
28.65
(20.3–40.3)
Levoﬂoxacin 1.0 3.2
(1.4–3.9)
9.5
(5.1–10.8)
5.4
(1.3–21.7)
23.19
(13.3–40.3)
SPN 731
(type 14)
WCK 771 0.25 10.0
(3.2–25.5)
20.0
(13.4–64.5)
17.8
(7.0–45.4)
53.12
(36.6–76.97)
Levoﬂoxacin 1.0 7.5
(1.0–15.8)
15.0
(5.0–46.9)
15.9
(12.5–20.1)
25.6
(19.3–34.13)
SPN 733
(type 7B)
WCK 771 0.25 50
(28.4–53.12)
75
(39.5–188.6)
45.5
(37.0–56.1)
84.4
(58.2–122.2)
Levoﬂoxacin 1.0 50
(22.4–57.8)
75
(40.1–147.9)
43.3
(36.4–51.5)
71.3
(56–90.7)
aRoute of infection: intraperitoneal. Infecting dose: 2–3 · 108 CFU ⁄ animal. Treatment: 1 h and 4 h post-infection.
Observation period: 7 days. Endpoint: percentage survival on day 7.
bMIC determination by agar dilution.
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lungs in 60% of animals, compared with 40% for
WCK 771; however, at a dose of 100 mg ⁄ kg, both
WCK 771 and levoﬂoxacin resulted in 100% of
animals having sterile lungs.
DISCUSSION
WCK 771 is an experimental quinolone that is
being developed for clinical use. Preliminary data
presented in 2001 indicated that WCK 771 has
improved potency against staphylococci, inclu-
ding methicillin-resistant strains, compared to
other quinolones (41st Interscience Conference
on Antimicrobial Agents and Chemotherapy,
abstracts F-539, F-541 and F-542). MIC50 and
MIC90 values (mg ⁄L) of WCK 771 for quinolone-
susceptible staphylococci were 0.008–0.015 and
0.015–0.03, compared to levoﬂoxacin values of
0.125 and 0.25, respectively. Against quinolone-
resistant staphylococci, WCK 771 MIC50 and
MIC90 values (mg ⁄L) were 0.5 and 1, compared
to 8 and 32 for levoﬂoxacin, respectively (abstract
F-542), while anti-pneumococcal MICs were
reported to be about one dilution lower than
those of levoﬂoxacin (abstract F-541). The results
of the current study supported these preliminary
ﬁndings, in that anti-pneumococcal MICs were
one or two dilutions lower than those of levoﬂ-
oxacin. MICs of other quinolones for S. pneumo-
niae were consistent with those reported
previously [4,5,15–19,31,32]. MICs of non-quino-
lone agents against pneumococci were similar to
those described previously, with higher cefurox-
ime and macrolide MICs for isolates with raised
penicillin MICs [4,5,16–19].
In the present study, clinaﬂoxacin, which is no
longer being developed, had the lowest MICs of
the agents tested for all pneumococcal isolates,
followed by moxiﬂoxacin, gatiﬂoxacin, WCK 771,
levoﬂoxacin and ciproﬂoxacin. Quinolone efﬂux
was present in 12 of the 25 quinolone-resistant
pneumococcal isolates studied, mainly affecting
ciproﬂoxacin, which is consistent with published
data regarding this mechanism in c. 50% of
quinolone-resistant pneumococcal isolates [33].
The activity of WCK 771 was not affected by the
presence of a quinolone efﬂux mechanism in
quinolone-resistant S. pneumoniae isolates. How-
ever, the activity of WCK 771 against quinolone-
resistant pneumococci (MIC50 ⁄ 90 values of
4 ⁄ 8 mg ⁄L) was not as good as its activity against
quinolone-susceptible pneumococci (MIC50 ⁄ 90
values of 0.5 ⁄ 0.5 mg ⁄L). Thus, the activity of
WCK 771 against quinolone-resistant pneumo-
cocci is four- to eight-fold lower than that against
quinolone-resistant staphylococci (MIC50 ⁄ 90
values of 0.5 ⁄ 1 mg ⁄L).
The results of time-kill studies showed that
WCK 771 was bactericidal if pneumococci, inclu-
ding the one quinolone-resistant isolate tested,
were exposed to this agent for 24 h. The bacteri-
cidal activities of other quinolones were similar to
those found in previous studies [19,28,34,35].
The results of the animal model studies sug-
gested that the activity of WCK 771 against
pneumococci was comparable to that of levoﬂ-
oxacin, with ED50 values of 3–50 mg ⁄ kg for both
agents by both the oral and subcutaneous routes
in a systemic mouse infection model, and with
comparable results being obtained with
100 mg ⁄ kg for both agents in pneumococcal lung
load-reduction studies.
In summary, WCK 771 showed superior
potency to older agents (ciproﬂoxacin, levoﬂoxa-
cin) and similar potency to newer agents
(gatiﬂoxacin, moxiﬂoxacin) against quinolone-
susceptible pneumococci. However, as with other
quinolones, activity against quinolone-resistant
isolates was considerably lower. During the
dose-escalation stage of phase I studies, a favour-
able safety and human pharmacokinetic proﬁle
resulted in sustained drug levels above the MIC90
for quinolone-susceptible pneumococci, as well as
methicillin-resistant staphylococci. On the basis of
these observations, WCK 771 has the potential to
provide coverage against methicillin-resistant sta-
phylococci as well as quinolone-susceptible pneu-
mococci.
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